Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Watch or Listen to JNMT Podcast
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Follow SNMMI on Twitter
  • Subscribe to JNMT RSS feeds
Research ArticleIMAGING

Impact of 18F-FDG PET/CT with Retrograde Filling of the Urinary Bladder in Patients with Suspected Pelvic Malignancies

Ana Maria Garcia Vicente, Angel Soriano Castrejón, Azahara Palomar Muñoz, Patrick Pilkington Woll and Alicia Nuñez García
Journal of Nuclear Medicine Technology September 2010, 38 (3) 128-137; DOI: https://doi.org/10.2967/jnmt.109.074146
Ana Maria Garcia Vicente
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angel Soriano Castrejón
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Azahara Palomar Muñoz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Pilkington Woll
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alicia Nuñez García
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    (A) Supine pelvic acquisition with retrograde filling of urinary bladder. Residual urine in dependent area of urinary bladder shows 18F-FDG activity. (B) Second set of images was acquired with patient prone and shows clearance of residual urinary activity.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Patient with invasive colon cancer (sigmoid) that had gynecologic and ureteral involvement and was treated with surgery and chemotherapy. PET was requested because of suspected disease progression (vaginal mass on diagnostic CT scan). Images after retrograde filling of bladder (A and C) show vaginal involvement in sagittal projections (A) and two 18F-FDG foci in posterior bladder wall in axial projections (C) that were missed in standard acquisition (B). Lateral 18F-FDG deposit corresponds to ureter, and medial deposit (arrow), with a nodular lesion on CT image, corresponds to physiologic ureteral junction (false-positive).

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Impact of retrograde filling of urinary bladder in ruling out or verifying bladder involvement. Patient had bladder cancer, and PET was requested for staging. (A) Pelvic axial PET image (right) shows bladder activity in anterior wall corresponding to anterior wall tumor thickening on CT (left). (B) Pelvic axial PET image with retrograde filling shows higher uptake in anterior wall, better defining lesion.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Impact of retrograde filling of urinary bladder in ruling out or verifying gynecologic involvement. Patient had bladder cancer and was treated with transurethral resection. Diagnostic CT scan showed diffuse bladder wall thickening and hypodense lesion in left ovary. (A) Standard PET image (center) shows uptake in posterior bladder wall, corresponding to wall thickening on CT (left), although image seems to show metabolic involvement of uterus (arrow). (B) Images with retrograde bladder filling better define bladder lesion and exclude uterus involvement. Histopathologic assessment (cystectomy plus hysterectomy) showed only residual bladder cancer.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Impact of retrograde filling of urinary bladder in ruling out or verifying rectal involvement. Patient had surgically treated rectal cancer, and liver metastases were suspected. (A) Standard PET pelvic image (center) shows almost emptied bladder, with posterior extension close to rectal wall (arrow). (B) PET image with retrograde bladder filling shows complete disappearance of bladder 18F-FDG activity, ruling out rectal malignancy.

Tables

  • Figures
    • View popup
    TABLE 1

    Distribution of Patients and Results

    Study no.Patient no.Cancer historyAge (y)SexPrevious treatmentLocation of pathology on CT scanBladder wall thicknessPET (+) pelvisPET (+) other locationPET (+) bladderPET (+) totalFinal disease statusClassification of pelvisOverall classification
    11Cervix (A)54FSurgery plus radiotherapyPelvisDiffuseCervixNoNoYesRecurrence*True-positiveTrue-positive
    22Testicle76MSurgeryPelvisPosterior lateral wallSpermatic cordonNoNoYesComplete remissionFalse-positiveFalse-positive
    33Bladder72MTURPelvisPosterior lateral plus lymphadenopathiesProstateNoNoYesComplete remission*False-positiveFalse-positive
    44Cervix (A)50FSurgery plus radiotherapy——NoNoNoNoComplete remissionTrue-negativeTrue-negative
    55Bladder (A)44MTUR plus radiotherapyPulmonary nodules plus pelvisPosterior wallNoMediastinumNoYesRecurrenceTrue-negativeTrue-positive
    66Bladder (A)78FTURPulmonary nodules plus pelvisDiffuseBladderNoYesYesRecurrence*True-positiveTrue-positive
    77Prostate and bladder (A)67MTUR plus radiotherapyPulmonary nodules plus pelvisDiffuseNoNoNoNoComplete remissionTrue-negativeTrue-negative
    88Rectal (A)56FSurgery, chemotherapy, and radiotherapyRenal (?)NoPresacrumNoYes (false-positive)YesRecurrence*True-positiveTrue-positive
    99Uterus (A)54FSurgery, radiotherapy, and chemotherapyPelvis (ascitis)NoNoNoNoYesComplete remissionTrue-negativeFalse-positive
    1010Bladder and lung76MSurgery plus intrabladder chemotherapyLung massNoNoLungNoYesSurgeryTrue-negativeTrue-positive
    1111Bladder (A)76MTUR, chemotherapy, and radiotherapyPelvisRight wallNoNoNoNoComplete remissionTrue-negativeTrue-negative
    1212Cervix (A)75FSurgery, chemotherapy, and radiotherapyPelvis (within the bladder)NoCervix–vaginaNoYesYesRecurrence*True-positiveTrue-positive
    1313Cervix69FSurgeryPelvis (vagina)NoVaginaNoNoYesRecurrence*True-positiveTrue-positive
    1414Gastric64FSurgeryPelvisAnterior–superior wallNoNoNoNoComplete remissionTrue-negativeTrue-negative
    1515Cervix (A)71FSurgery, radiotherapy, and chemotherapyPelvis (cervix)NoCervixPulmonary solitary noduleNoYesComplete remission*False-positiveFalse-positive
    1616Prostate70MRadiotherapy——NoBone chemotherapyNoYesRecurrenceTrue-negativeTrue-positive
    1717Bladder plus urothelial66MTUR plus nephroureterectomyNoNoNoNoNoNoComplete remissionTrue-negativeTrue-negative
    1818Anal (A)67FChemotherapy plus radiotherapyPelvis (anal nodule)NoNoNoNoNoComplete remissionTrue-negativeTrue-negative
    1915Cervix (scan 2)Surgery, radiotherapy, and chemotherapyPET/CTNoNoPulmonary solitary nodule ↓NoNoComplete remissionTrue-negativeTrue-negative
    2019Renal plus bladder (A)59MTUR——NoNoNoNoComplete remission*True-negativeTrue-negative
    2120Cervix (A)41FChemotherapy plus radiotherapyPelvis: MRI (fibrothecoma)NoNoNoNoNoComplete remissionTrue-negativeTrue-negative
    2221Bladder (A)80MChemotherapy plus radiotherapyPelvisDiffuse plus lymphadenopathiesProstateSuprarenal, lymphadenopathiesYesYesRecurrenceTrue-positiveTrue-positive
    2322Bladder and lung74MURLung massNoBladderLungYesYesStaging*True-positiveTrue-positive
    245Bladder (scan 2)TUR plus radiotherapy——NoNoNoNoComplete remissionTrue-negativeTrue-negative
    255Bladder (scan 3)TUR plus radiotherapy——NoNoNoNoComplete remissionTrue-negativeTrue-negative
    261Cervix (scan 2)Chemotherapy plus radiotherapy——Pelvic massesNoNoYesProgressionTrue-positiveTrue-positive
    271Cervix (scan 3)Surgery plus radiotherapyPelvis (masses)NoPelvic massesNoNoYesRecurrenceTrue-positiveTrue-positive
    2823Ovarian mass64F—†Pelvis (ovarian mass)NoNoNoNoNoStaging*True-negativeTrue-negative
    2924Sigmoid colon IV (A)73FSurgery plus chemotherapyPelvis (vaginal mass)NoVaginaLymph nodeYes (false-positive)YesStaging*True-positiveTrue-positive
    3025Bladder79FTURPelvisAnterior wallYesNoYesYesRecurrenceTrue-positiveTrue-positive
    3126Colon IV (A)48FSurgery plus chemotherapyLiverNoNoNoNoYesRecurrenceTrue-negativeTrue-positive
    3227Bladder50MPartial resection‡——NoNoNoNoComplete remissionTrue-negativeTrue-negative
    3328Cervix55FChemotherapy plus radiotherapy——NoNoNoNoComplete remissionTrue-negativeTrue-negative
    3429Urothelial (A)63FNephroureterectomy plus chemotherapyPelvisDiffuseUreter–bladder junctionSuprarenalYesYesRecurrence*True-positiveTrue-positive
    3530Ovarian IV (A)44FSurgery plus chemotherapyPelvis (pelvic mass)—Pelvic massLymph nodeNoYesRecurrenceTrue-positiveTrue-positive
    3631Rectal (A)67FSurgeryLiver—NoLiver plus lymph nodeNoYesRecurrenceTrue-negativeTrue-positive
    3732Uterus56FSurgery——CervixNoNoYesComplete remission*False-positiveFalse-positive
    3833Rectal (A)76FSurgery, chemotherapy, and radiotherapyPulmonary nodules—NoLungNoYesRecurrenceTrue-negativeTrue-positive
    3934Uterus (A)73FSurgery——NoNoNoNoComplete remissionTrue-negativeTrue-negative
    4035Bladder and lung81M—†Lung mass—BladderLungYesYesStaging*True-positiveTrue-positive
    4136Bladder76MSurgery, radiotherapy, and chemotherapyPelvisDiffuseBladderNoYes (false-positive)YesHemorrhagic cystitisFalse-positiveFalse-positive
    4237Unknown origin tumor47M—†Lung nodule plus lymphadenopathiesNoNoLung plus lymph nodeNoYesStagingTrue-negativeTrue-positive
    4338Rectal (A)MSurgery, chemotherapy, and radiotherapy——NoNoNoNoComplete remissionTrue-negativeTrue-negative
    • ↵* Histopathologic confirmation.

    • ↵† No previous chemotherapy.

    • ↵‡ Partial resection, without clean surgical margins.

    • A = locally advanced; PET (+): PET-positive suggestion of malignancy; TUR: transurethral resection of bladder malignancy; ↓ = decreased in size and metabolism; IV = distant metastases.

    • View popup
    TABLE 2

    Diagnostic Impact of Filled-Bladder Technique in Relation to Suspected Pathology

    ImpactNo. of patients
    Rule out or verify bladder involvement26
    Rule out or verify gynecologic involvement4
    Rule out rectal involvement2
    Better define disease
     Gynecologic3
     Pelvic4
    No impact4*
    • ↵* Two of these 4 had suboptimal technique, but it did not interfere with interpretation.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 38 (3)
Journal of Nuclear Medicine Technology
Vol. 38, Issue 3
September 1, 2010
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Impact of 18F-FDG PET/CT with Retrograde Filling of the Urinary Bladder in Patients with Suspected Pelvic Malignancies
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Impact of 18F-FDG PET/CT with Retrograde Filling of the Urinary Bladder in Patients with Suspected Pelvic Malignancies
Ana Maria Garcia Vicente, Angel Soriano Castrejón, Azahara Palomar Muñoz, Patrick Pilkington Woll, Alicia Nuñez García
Journal of Nuclear Medicine Technology Sep 2010, 38 (3) 128-137; DOI: 10.2967/jnmt.109.074146

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Impact of 18F-FDG PET/CT with Retrograde Filling of the Urinary Bladder in Patients with Suspected Pelvic Malignancies
Ana Maria Garcia Vicente, Angel Soriano Castrejón, Azahara Palomar Muñoz, Patrick Pilkington Woll, Alicia Nuñez García
Journal of Nuclear Medicine Technology Sep 2010, 38 (3) 128-137; DOI: 10.2967/jnmt.109.074146
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Early 10-Minute Postinjection [18F]F-FAPI-42 uEXPLORER Total-Body PET/CT Scanning Protocol for Staging Lung Cancer Using HYPER Iterative Reconstruction
  • Single- Versus Dual-Time-Point Imaging for Transthyretin Cardiac Amyloid Using 99mTc-Pyrophosphate
  • Does Arthrography Improve Accuracy of SPECT/CT for Diagnosis of Aseptic Loosening in Patients with Painful Knee Arthroplasty: A Systematic Review and Metaanalysis
Show more Imaging

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire